Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 1999

View Archived Issues

Sitafloxacin: clinically useful fluoroquinolone

Licensing opportunity from the NIH: immunotoxins directed against malignant B-cells

Genset seeks patents for two genes associated with zileuton-induced hepatotoxicity

Licensing opportunity from NIH: broad-spectrum chemokine antagonist

Cerep and Bristol-Myers Squibb announce collaborative agreements

Viragen updates development programs

IDE granted to Gliatech for ADCON-A

Second quarter highlights summarized by SB

Tachykinin antagonists now proposed for attention deficit disorders

Water-soluble antitumor camptothecins reported by Japanese labs

Novel series of PDE4 inhibitors from Byk Gulden particularly useful for asthma prophylaxis

Inhibitors of Src family SH2 domains in early-stage development at Boehringer Ingelheim

Fujisawa investigators disclose dual adenosine A1/A2 receptor antagonists

New antiasthmatic agent in the pipeline at Nikken Chemicals

Aminomethylchromanes with potential for dyspepsia disclosed by Janssen

AstraZeneca claims new immunosuppressants for asthma, bronchitis, rhinitis, etc.

Roche summarizes financial and development highlights during first half of 1999

OraSolv Zomig receives first regulatory approval in Sweden for migraine

Antisense oligonucleotides specific for TS mRNA sequences enhance FdUrd cytotoxicity

Dosing discontinued in phase II MS trial of MSP-771

sNDA submitted for AmBisome for cryptococcal meningitis in AIDS patients

Ro-64-0796/GS-4104: potential drug interactions and beneficial effects in patients with the flu

New depsipeptides produced by sponges possess anti-HIV and antitumor effects

Molecular modeling yields new antiestrogenic and antitumor antineoplaston A10 analogues

Postischemic neuroprotective efficacy of LY-341122 reported at Brain '99

Brain '99: lanoteplase improves microcirculation in ischemic brain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...